This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Gilead Sciences (GILD) and Celcuity (CELC)

Tipranks - Tipranks - Thu Jun 4, 4:44AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Travere Therapeutics (TVTX), Gilead Sciences (GILD) and Celcuity (CELC) with bullish sentiments.

Claim 55% Off TipRanks

Travere Therapeutics (TVTX)

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Travere Therapeutics, with a price target of $50.00. The company’s shares closed last Tuesday at $42.96.

According to TipRanks.com, Bansal is a 5-star analyst with an average return of 9.4% and a 55.7% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., BioMarin Pharmaceutical, and Vertex Pharmaceuticals. ;'>

Currently, the analyst consensus on Travere Therapeutics is a Strong Buy with an average price target of $54.92, representing a 24.3% upside. In a report issued on May 29, J.P. Morgan also maintained a Buy rating on the stock with a $53.00 price target.

See today’s best-performing stocks on TipRanks >>

Gilead Sciences (GILD)

In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Gilead Sciences, with a price target of $162.00. The company’s shares closed last Tuesday at $127.57.

According to TipRanks.com, Ahmad is a 4-star analyst with an average return of 3.3% and a 52.4% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., Ultragenyx Pharmaceutical, and Bicara Therapeutics Inc. ;'>

Gilead Sciences has an analyst consensus of Strong Buy, with a price target consensus of $159.95, implying a 24.0% upside from current levels. In a report issued on May 20, Maxim Group also upgraded the stock to Buy with a $165.00 price target.

Celcuity (CELC)

Wells Fargo analyst Eva Fortea Verdejo reiterated a Buy rating on Celcuity yesterday and set a price target of $166.00. The company’s shares closed last Tuesday at $91.42.

According to TipRanks.com, Verdejo is a 5-star analyst with an average return of 35.3% and a 63.8% success rate. Verdejo covers the Healthcare sector, focusing on stocks such as Bicara Therapeutics Inc., Zentalis Pharmaceuticals, and Kiniksa Pharmaceuticals. ;'>

Celcuity has an analyst consensus of Strong Buy, with a price target consensus of $170.25, a 79.2% upside from current levels. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $165.00 price target.

Read More on TVTX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).